International Immunology, Vol. 12, No. 10, 1449-1457,
October 2000
© 2000 Japanese Society for Immunology
Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-ß-secreting cells and suppressing chemokine expression
1 Department of Medical Microbiology and Immunology, Göteborg University, 413 46 Göteborg, Sweden
2 Division of Neurology, Karolinska Institute, Huddinge Hospital, 141 86 Stockholm, Sweden
Correspondence to: J. Holmgren
The efficacy and mechanism of immunosuppression against experimental autoimmune encephalomyelitis (EAE) by oral low-dose administration of myelin basic protein (MBP) conjugated to cholera toxin B subunit (CTB) were investigated in Lewis rats immunized with MBP together with complete Freund's adjuvant 4 days before the start of treatment. Oral treatment with CTB–MBP conjugate gave almost complete protection against disease, an effect that was totally abrogated by including a low dose of cholera holotoxin (CT). The protection by CTB–MBP was associated with a dramatic reduction in the number of leukocytes staining for CD4, CD8, IL-2R or MHC class II in the spinal cord as examined by immunohistochemistry. The mRNA expressions of Th1 cytokines IFN-
, IL-12 and tumor necrosis factor-
, as well as of chemokines monocyte chemotactic protein (MCP)-1 and RANTES in the spinal cord were also reduced by 76–94%, as assessed by in situ hybridization. In contrast, transforming growth factor (TGF)-ß mRNA-expressing cells were strongly increased in the spinal cord from animals treated orally with the CTB–MBP conjugate. In the draining peripheral lymph nodes, the number of MBP-specific TGF-ß mRNA-expressing cells was also increased, whereas there was a decrease in cells expressing Th1 or Th2 cytokine mRNA. Protection against EAE could be transferred by injection of cells from the mesenteric lymph nodes of animals fed with CTB–MBP into naive animals exposed to encephalitogenic T cells. The results indicate that the protective anti-inflammatory effect by oral treatment with CTB–MBP conjugate is, to a large extent, due to the induction of TGF-ß-secreting suppressive-regulatory T cells and to local down-regulation of MCP-1 and RANTES in the spinal cord.
Keywords: cholera toxin B subunit, experimental autoimmune encephalomyelitis, myelin basic protein, transforming growth factor-ß
3 Present address: INSERM UNITE 364, Faculté de Médicine-Pasteur, Avenue de Vallombrose, 06107 Nice Cedex 02, France
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. D'Ambrosio, M. Colucci, O. Pugliese, F. Quintieri, and M. Boirivant Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation J. Leukoc. Biol., September 1, 2008; 84(3): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-B. Sun, S. Raghavan, A. Sjoling, S. Lundin, and J. Holmgren Oral Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Generates Both Foxp3+CD25+ and Foxp3-CD25- CD4+ Regulatory T Cells J. Immunol., December 1, 2006; 177(11): 7634 - 7644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E M Coccia, M E Remoli, C Di Giacinto, B Del Zotto, E Giacomini, G Monteleone, and M Boirivant Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease Gut, November 1, 2005; 54(11): 1558 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bo Su, P. B. Silver, P. Wang, C.-C. Chan, and R. R. Caspi Cholera Toxin Prevents Th1-Mediated Autoimmune Disease by Inducing Immune Deviation J. Immunol., July 15, 2004; 173(2): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Lavelle, A. Jarnicki, E. McNeela, M. E. Armstrong, S. C. Higgins, O. Leavy, and K. H. G. Mills Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent J. Leukoc. Biol., May 1, 2004; 75(5): 756 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Riminton, R. Kandasamy, D. Dravec, A. Basten, and A. G. Baxter Dermal Enhancement: Bacterial Products on Intact Skin Induce and Augment Organ-Specific Autoimmune Disease J. Immunol., January 1, 2004; 172(1): 302 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Biet, L. Kremer, I. Wolowczuk, M. Delacre, and C. Locht Immune Response Induced by Recombinant Mycobacterium bovis BCG Producing the Cholera Toxin B Subunit Infect. Immun., May 1, 2003; 71(5): 2933 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fujino, N. Funeshima, Y. Kitazawa, H. Kimura, H. Amemiya, S. Suzuki, and X.-K. Li Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 70 - 77. [Abstract] [Full Text]
|
|
|
|
|
|
V. Burkart, Y.-E. Kim, B. Hartmann, I. Ghiea, U. Syldath, M. Kauer, W. Fingberg, P. Hanifi-Moghaddam, S. Muller, and H. Kolb Cholera Toxin B Pretreatment of Macrophages and Monocytes Diminishes Their Proinflammatory Responsiveness to Lipopolysaccharide J. Immunol., February 15, 2002; 168(4): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|